Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Meriranta

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|May 22, 2025
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell LymphomaLeo Meriranta, Rasmus Rask Kragh Jørgensen, Annika Pasanen, et al.
Blood Advances|December 19, 2023
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trialMats Jerkeman, Arne Kolstad, Martin Hutchings, et al.
Blood|December 21, 2021
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphomaLeo Meriranta, Amjad Alkodsi, Annika Pasanen, et al.
Hemasphere|May 13, 2025
Biomarker-adapted treatment in high-risk large B-cell lymphomaSirpa Leppä, Leo Meriranta, Maare Arffman, et al.
Blood Advances|May 8, 2020
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxisSirpa Leppä, Judit Jørgensen, Anne Tierens, et al.
Cancer Cell|July 11, 2020
Immunogenomic Landscape of Hematological MalignanciesOlli Dufva, Petri Pölönen, Oscar Brück, et al.
Cell|October 7, 2017
Genetic and Functional Drivers of Diffuse Large B Cell LymphomaAnupama Reddy, Jenny Zhang, Nicholas S Davis, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|May 22, 2025
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell LymphomaLeo Meriranta, Rasmus Rask Kragh Jørgensen, Annika Pasanen, et al.
Blood Advances|December 19, 2023
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trialMats Jerkeman, Arne Kolstad, Martin Hutchings, et al.
Blood|December 21, 2021
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphomaLeo Meriranta, Amjad Alkodsi, Annika Pasanen, et al.
Hemasphere|May 13, 2025
Biomarker-adapted treatment in high-risk large B-cell lymphomaSirpa Leppä, Leo Meriranta, Maare Arffman, et al.
Blood Advances|May 8, 2020
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxisSirpa Leppä, Judit Jørgensen, Anne Tierens, et al.
Cancer Cell|July 11, 2020
Immunogenomic Landscape of Hematological MalignanciesOlli Dufva, Petri Pölönen, Oscar Brück, et al.
Cell|October 7, 2017
Genetic and Functional Drivers of Diffuse Large B Cell LymphomaAnupama Reddy, Jenny Zhang, Nicholas S Davis, et al.
Pageof 2